The U.S. Federal Trade Commission is probing complaints about telehealth platform Hims & Hers regarding its advertising and ...

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

Hims & Hers first told investors about a regulatory review in July 2024, but Bloomberg's report adds new color on what ...

Hims & Hers Health (NYSE:HIMS) stock fell 4.1% in after-hours trading on Thursday following a Bloomberg report that revealed ...

For more than a year, the Federal Trade Commission has been investigating Hims & Hers Health Inc.’s business practices, including whether it has made it too hard for customers to cancel subscriptions, ...

The U.S. Federal Trade Commission is probing complaints about Telehealth platform Hims & Hers regarding its advertising and ...

After Bloomberg reported, citing people familiar with the probe, that the Federal Trade Commission has been investigating ...

Shares of Hims & Hers (HIMS) are down 92c, or 2%, to $45.09 in pre-market trading after GoodRx (GDRX) announced that all strengths of Ozempic and Wegovy pens are available to eligible self-paying ...

Investing.com -- Hims & Hers Health (NYSE:HIMS) stock dropped 2.6% on Friday following reports that the Federal Trade Commission has been investigating the telehealth company's business practices for ...

Recent health-related developments include Britain's decisions on the bioethanol industry, Berkshire Hathaway's new stake in ...